Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
Technology continues to impact disease state management in remarkable ways. Monitoring of patients with diabetes is no exception. Both the American Diabetes Association and American Association of Clinical Endocrinologists/American College of Endocrinology make light...
The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown...
SGLT2s like empagliflozin, dapagliflozin, ertugliflozin, and canagliflozin are getting more use in diabetes care as time goes on. As a geriatric pharmacist, I certainly recognize that these agents have a lot of potential benefits, but they can also have adverse...
I was asked this question the other day and I wanted to specifically address it. What should I do if I didn’t take Rybelsus (semaglutide) 30 minutes before I ate because the package insert says I’m supposed to be taking Rybelsus with food? Rybelsus has...
